Cargando…

Nonmuscle invasive bladder cancer: a primer on immunotherapy

Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maruf, Mahir, Brancato, Sam J., Agarwal, Piyush K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Anti-Cancer Association 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944546/ https://www.ncbi.nlm.nih.gov/pubmed/27458527 http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0020

Ejemplares similares

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Diagnostics techniques in nonmuscle invasive bladder cancer
por: Soubra, Ayman, et al.
Publicado: (2015)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
por: Lilge, Lothar, et al.
Publicado: (2020)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy
por: Rao, Manoj V., et al.
Publicado: (2013)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer (Erratum)
por: Lilge, Lothar, et al.
Publicado: (2020)

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study
por: Jian, Xiaoming, et al.
Publicado: (2019)

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
por: Wettstein, Marian S., et al.
Publicado: (2015)

Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCG
por: Strich, Jeffrey R., et al.
Publicado: (2017)

Efficacy of pirarubicin for nonmuscle invasive bladder cancer: A protocol of systematic review and meta-analysis
por: Chen, Da-Yin, et al.
Publicado: (2020)

New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer
por: Ather, M Hammad, et al.
Publicado: (2015)

Assessment of Pain Management, Acceptance of Illness, and Adjustment to Life with Cancer in Patients with Nonmuscle Invasive Bladder Cancer
por: Krajewski, Wojciech, et al.
Publicado: (2018)

Erectile dysfunction in nonmuscle-invasive bladder cancer patients before and after transurethral resection (TUR) of bladder tumor in China
por: Guo, Peng, et al.
Publicado: (2021)

MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer
por: Mitash, Nilay, et al.
Publicado: (2017)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
por: Joshua, Julie Mariam, et al.
Publicado: (2019)

Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients
por: Lu, Mengxin, et al.
Publicado: (2019)

A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer
por: Bellat, Vanessa, et al.
Publicado: (2022)

Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder
por: Lim, So Dug, et al.
Publicado: (2015)

Nonmuscle Tissues Contribution to Cancer Cachexia
por: Argilés, Josep M., et al.
Publicado: (2015)

Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer
por: Kim, Young-Won, et al.
Publicado: (2015)

Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer
por: Tsuji, Shingo, et al.
Publicado: (2016)

Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol
por: Rutherford, Claudia, et al.
Publicado: (2017)

Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis
por: Zhang, Dong, et al.
Publicado: (2020)

Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?
por: Yılmaz, Yüksel, et al.
Publicado: (2018)

The role of transcavitary ultrasonography in diagnosis and staging of nonmuscle-ınvasive bladder cancer: a prospective non-randomized clinical study
por: Oktem, Gultekin Cagri, et al.
Publicado: (2014)

Pembrolizumab in bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057)
por: Kumar, Bhuwan
Publicado: (2021)

Primer on tumor immunology and cancer immunotherapy
por: Harris, Timothy J, et al.
Publicado: (2013)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Nonmuscle myosin-2: mix and match
por: Heissler, Sarah M., et al.
Publicado: (2012)

EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification
por: Wang, Hui, et al.
Publicado: (2018)

Regulation of motility in nonmuscle cells
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_k5s0vj1cvaunpruqatcj5m375i